Disruption of Human Papillomavirus 16 E6/E7 Genes Using All-in-One Adenovirus Vectors Expressing Eight Double-Nicking Guide RNAs
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26178685 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Megumi Yamaji und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center of Biomedical Research Resources, Juntendo University School of Medicine, Tokyo 113-8421, Japan. Hauptthemen laut MEDLINE: Oncogene Proteins, Viral, RNA, Guide, CRISPR-Cas Systems, Papillomavirus E7 Proteins, Adenoviridae. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, JSPS KAKENHI.
Abstract (Originalsprache)
Human papillomavirus (HPV) is a prime target for genome-editing therapy as its E6 and E7 oncogenes are crucial for cancer development and maintenance. A key challenge in CRISPR/Cas9 therapy is the off-target effects. This study utilized a double-nicking technique to introduce DNA breaks in the E6 and E7 regions of HPV16. From 146 gRNA candidates, 16 double-nicking pairs were selected. Multiple combinations of double-nicking (DN)-gRNA pairs were delivered to HPV16-positive cells via lentiviruses, followed by Cas9 nickase (Cas9n) expression. Combinations of 3–4 DN-gRNA pairs effectively killed HPV16-positive cells while sparing HPV-negative cells. Off-target effects were reduced by nearly three orders of magnitude. An “all-in-one” adenovirus (AdV) system expressing four gRNA pairs and Cas9n showed promise in inhibiting tumor growth in HPV16-positive cancer models, demonstrating its potential as a safe and effective treatment for HPV-induced tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Biomedical Research Resources, Juntendo University School of Medicine, Tokyo 113-8421, Japan.
- National Cancer Center Research Institute, Tokyo 466-0045, Japan.
- Division of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
- Department of Pharmaceutical Engineering, Faculty of Engineering, Toyama Prefectural University, Toyama 939-0398, Japan.
- Laboratory of Virology, Institute of Microbial Chemistry (BIKAKEN), Microbial Chemistry Foundation, Tokyo 141-0021, Japan.
- Division of Health Medical Intelligence, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
ORCID-Profile: Satomi Aoyama-Kikawa, Yoichi Furukawa, Rika Kasajima, Iwao Kukimoto, Tohru Kiyono
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
- JSPS KAKENHI
Zitieren
APA
Yamaji, M., Nakahara, T., Nakanishi, T., Aoyama-Kikawa, S., Yamaguchi, K., Furukawa, Y., Nakamura, M., Okada, T., Tabata, H., Fuse, R., Shimizu, E., Kasajima, R., Imoto, S., Kukimoto, I., Saito, I., & Kiyono, T. (2025). Disruption of Human Papillomavirus 16 E6/E7 Genes Using All-in-One Adenovirus Vectors Expressing Eight Double-Nicking Guide RNAs. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26178685
Vancouver
Yamaji M, Nakahara T, Nakanishi T, Aoyama-Kikawa S, Yamaguchi K, Furukawa Y, et al. Disruption of Human Papillomavirus 16 E6/E7 Genes Using All-in-One Adenovirus Vectors Expressing Eight Double-Nicking Guide RNAs. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26178685
BibTeX
@article{Yamaji2025,
author = {Yamaji, Megumi and Nakahara, Tomomi and Nakanishi, Tomoko and Aoyama-Kikawa, Satomi and Yamaguchi, Kiyoshi and Furukawa, Yoichi and Nakamura, Mariko and Okada, Tadashi and Tabata, Hirotaka and Fuse, Ryoko and Shimizu, Eigo and Kasajima, Rika and Imoto, Seiya and Kukimoto, Iwao and Saito, Izumu and Kiyono, Tohru},
title = {Disruption of Human Papillomavirus 16 E6/E7 Genes Using All-in-One Adenovirus Vectors Expressing Eight Double-Nicking Guide RNAs},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26178685}
}
EUVIMED